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ABSTRACT Platelets are increasingly recognized to play a role in the complications
of Streptococcus pneumoniae infections. S. pneumoniae expresses neuraminidases,
which may alter glycans on the platelet surface. In the present study, we investi-
gated the capability of pneumococcal neuraminidase A (NanA) to remove sialic acid
(desialylation) from the platelet surface, the consequences for the platelet activation
status and reactivity, and the ability of neuraminidase inhibitors to prevent these ef-
fects. Our results show that soluble NanA induces platelet desialylation. Whereas de-
sialylation itself did not induce platelet activation (P-selectin expression and platelet
ﬁbrinogen binding), platelets became hyperreactive to ex vivo stimulation by ADP
and cross-linked collagen-related peptide (CRP-XL). Platelet aggregation with leuko-
cytes also increased. These processes were dependent on the ADP pathway, as in-
hibitors of the pathway (apyrase and ticagrelor) abrogated platelet hyperreactivity.
Inhibition of NanA-induced platelet desialylation by neuraminidase inhibitors (e.g.,
oseltamivir acid) also prevented the platelet effects of NanA. Collectively, our ﬁnd-
ings show that soluble NanA can desialylate platelets, leading to platelet hyperreac-
tivity, which can be prevented by neuraminidase inhibitors.
KEYWORDS Streptococcus pneumoniae, NanA, platelets, sialic acid, desialylation
Streptococcus pneumoniae is a major cause of community-acquired pneumonia andinvasive infections (1). S. pneumoniae is known to activate platelets via different
mechanisms, including through engagement of the immune receptor FcRIIA and the
integrin IIb3 and by activation of Src and Syk tyrosine kinases (2). A role for Toll-like
receptor 2 (TLR-2) in pneumococcus-induced platelet activation has also been pro-
posed (3), but with contradictory results (4). Thrombocytopenia, which may result from
platelet activation, is an independent predictor of mortality in severe pneumonia (5).
Whether platelet desialylation by pneumococcal neuraminidase A (NanA) is another
mechanism of platelet activation by S. pneumoniae is still unknown.
The importance of platelets in processes beyond hemostasis and coagulation is
increasingly appreciated (6). Activated platelets release different immune molecules,
modulate the response of leukocytes, and contribute to the formation of neutrophil
extracellular traps (NETs) that trap bacteria in the circulation, avoiding their further
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dissemination (7, 8). Furthermore, platelet activation may also increase the risk for
cardiovascular complications, which are common during S. pneumoniae infections (9).
Three genes encode neuraminidase (NA) activity in S. pneumoniae—nanA, nanB, and
nanC—among which only nanA is expressed by all pneumococci. The NanA protein is
located at the cell surface of pneumococci, where it is involved in the facilitation of
mucosal colonization (10, 11). Platelet surface glycoproteins (GPs) are decorated with
the N-acetylneuraminic acid (Neu5Ac) type of sialic acid (12), about 60% of which is
susceptible to cleavage by neuraminidase (13). Desialylation of platelets exposes
galactose residues and leads to platelet apoptosis, phagocytosis, and clearance from
the circulation by the Ashwell-Morel receptor (AMR) in the liver (14, 15). Grewal et al.
showed in a mouse model of pneumococcal sepsis that removal of desialylated
platelets by the AMR protected against disseminated intravascular coagulation (16).
Although NanA is well studied as a surface virulence factor (11, 17, 18), its effect on
platelet activation and function remains unclear, as well as whether neuraminidase
inhibitors, such as oseltamivir acid, are able to prevent these effects (19). Recently, two
main variants of NanA, containing the amino acids KGI or RAV at the catalytic site, were
reported to differ in enzyme kinetics and susceptibility to neuraminidase inhibitors (20).
It is unknown whether infection with either variant results in a different clinical
outcome.
The current study aimed to investigate the effects of soluble NanA on platelet
desialylation, platelet activation status, and platelet reactivity and to characterize the
pathways involved. Furthermore, the propensity of neuraminidase inhibitors and plate-
let function inhibitors to prevent these NanA effects on platelets was explored. Finally,
we studied whether the KGI and RAV variants of NanA had different effects on platelets
and whether these variants were associated with the platelet count in a cohort of
individuals with invasive pneumococcal infections.
RESULTS
Soluble NanA from S. pneumoniae desialylates platelets. To determine whether
NanA was released in the medium, supernatants from wild-type (WT) and nanA mutant
(nanA) pneumococci were analyzed by SDS-PAGE. The analysis showed a NanA band
of the expected size in the WT-derived supernatant, whereas the band was absent in
the mutant (see Fig. S1 in the supplemental material).
To study the effect of soluble NanA on the platelet surface sialic acid content,
washed platelets were exposed to supernatant with and without NanA, derived from
the WT and nanA mutant, respectively. Platelets incubated with NanA resulted in
reduced interaction of the sialic acid binding lectins Sambucus nigra lectin (SNA) and
Maackia amurensis lectin II (MALII) compared with platelets incubated without NanA,
indicating that NanA cleaved sialic acids from platelet surface glycoproteins (Fig. 1A
and B; see Fig. S2 in the supplemental material). Binding of SNA lectin on platelets
exposed to lower dilutions of nanA-derived supernatant tended to be higher than on
those exposed to phosphate-buffered saline (PBS) (Fig. 1A). This may be due to factors
in the supernatant that enhance binding of SNA to glycoproteins of nondesialylated
platelets. The different binding speciﬁcities of MALII, which binds to -2,3-sialoglycans,
and SNA, which binds to -2,6-sialoglycans, likely explain the differences in binding
patterns of the two lectins. Neuraminidase activity in the supernatants was 441.2
mol/min/liter and 58.9 mol/min/liter for supernatants with and without NanA,
respectively, as measured by the substrate hydrolysis assay. Based on the concentration
curve in Fig. 1, we chose to use the 1:400 dilution point in the subsequent experiments.
This dilution point is equivalent to 1.10 mol/min/liter and 0.14 mol/min/liter for
supernatants with and without NanA, respectively.
NanA exposure results in platelet hyperreactivity that is largely ADP signaling
dependent. Next, we studied the effects of NanA on platelet activation status and
platelet reactivity to ex vivo stimulation. Platelet-rich plasma (PRP) was exposed to NanA
for 1 h to assess platelet activation, with subsequent determination of platelet reactivity
by addition of increasing concentrations of the platelet agonists ADP, cross-linked
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collagen-related peptide (CRP-XL), and thrombin receptor activation peptide (TRAP).
There was no difference in the expression of the alpha-granule protein P-selectin and
binding of ﬁbrinogen following exposure to supernatant with or without NanA. In
contrast, following ex vivo stimulation with ADP and a low dose of CRP-XL, platelets
exposed to NanA showed higher P-selectin expression and ﬁbrinogen binding than the
control without NanA (Fig. 2A and B; see Fig. S3 in the supplemental material).
FIG 1 Binding of SNA and MALII lectins to NanA-exposed platelets. Binding of SNA (A) and MALII (B) lectins
to platelet surface sialic acid was determined after treating washed platelets with serial dilutions (1:80 to
1:10,000) of pneumococcal culture supernatants with (NanA) and without (NanA) NanA for 1 h at 37°C.
PBS and puriﬁed neuraminidase from C. perfringens (NA) were used as negative and positive controls,
respectively. The data are presented as mean ﬂuorescent intensity (MFI) plus SD (in arbitrary units [AU]) of
the results of two independent experiments with 3 replicates each (n  6). Differences between the
supernatants with and without NanA were analyzed using t tests. **, P 0.01; *, P 0.03; ns, not signiﬁcant.
The increase in desialylation with decreases in dilution of supernatants was analyzed using 1-way ANOVA
with posttest for the linear trend. For NanA supernatant, r2  0.73 and P  0.001 for SNA and r2  0.44
and P  0.001 for MALII; for NanA supernatant, r2  0.18 and P  0.06 for SNA and r2  0.65 and P 
0.001 for MALII.
FIG 2 Reactivity of NanA-exposed platelets to various platelet agonists. P-selectin (A) and ﬁbrinogen (B) expression
on platelets was determined after treating PRP with PBS (negative control), 200 mU puriﬁed neuraminidase from
C. perfringens (NA), or supernatant with (NanA) and without (NanA) NanA for 1 h at 37°C, followed by
stimulation with increasing concentrations of ADP, CRP-XL, or TRAP. The data are presented as MFI  SEM in
arbitrary units (n  10). Differences between NanA and NanA supernatants were analyzed using t tests.
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Stimulation with TRAP also induced higher ﬁbrinogen binding, but not P-selectin
expression, in NanA-exposed platelets. Similar results for ﬁbrinogen binding were
observed using washed platelets, indicating that plasma factors had no effects on the
observed outcome (see Fig. S4A in the supplemental material). However, unlike with
PRP, ﬁbrinogen binding was also slightly increased in desialylated platelets without
secondary stimulation, probably as a result of minimal platelet activation due to the
platelet isolation procedure. In order to identify the mechanisms of NanA-induced
platelet hyperreactivity involved, we focused on the ADP pathway, because the platelet
effects of NanA were more pronounced when ADP or CRP-XL was used as a platelet
stimulus than when TRAP was used. The effect of CRP-XL (collagen pathway) is also
known to depend on secondary ADP release (21). ADP signaling was inhibited using
apyrase, which hydrolyzes soluble ADP, and with ticagrelor, an inhibitor of the ADP
receptor P2Y12. Both apyrase and ticagrelor reduced NanA-induced platelet hyperre-
activity upon ex vivo stimulation with either CRP-XL or TRAP (Fig. 3), conﬁrming the
importance of the ADP signaling pathway.
NanA promotes dense-granule secretion and increases surface expression of
GPIIIa. Platelets contain large quantities of ADP in their dense granules, together with
other molecules, such as ATP, calcium, and serotonin. Secretion of ADP from dense
granules activates P2Y12, inducing ampliﬁcation of platelet activation. We show that
NanA promotes ADP-induced dense-granule secretion, as suggested by higher expres-
sion of the dense-granule marker CD63 on the platelet surface, together with a
reduction in intraplatelet mepacrine concentrations (Fig. 4A). Exposure of platelets to
NanA without a platelet agonist did not change mepacrine concentrations or CD63
expression, indicating that exposure to NanA alone is insufﬁcient to induce dense-
granule secretion.
Exposing platelet-rich plasma to increasing concentrations of NanA did not increase
binding of antibodies directed against the ADP receptor P2Y12, the collagen receptor
GPIV, or the VWF receptor GP1b (Fig. 4B). In contrast, a signiﬁcant increase in the
binding of antibodies against GPIIIa was observed (P  0.001), probably due to
increased exposure of antibody binding sites as a consequence of removal of sialic acid.
When associated with GPIIb, GPIIIa constitutes the receptor for ﬁbrinogen and other
adhesive proteins, such as VWF.
Neuraminidase inhibitors prevent NanA-induced platelet hyperreactivity. Next,
we explored whether neuraminidase inhibitors could prevent NanA-induced platelet
FIG 3 Effects of apyrase and ticagrelor on hyperreactivity of NanA-exposed platelets. P-selectin (A and B) and ﬁbrinogen (C and D)
expression on platelets was determined after treating PRP with PBS or supernatant containing NanA (NanA) for 1 h at 37°C, followed
by hydrolyzing ADP using 10 g/ml apyrase (A and C) or blocking ADP receptor using 50 g/ml ticagrelor (B and D) for 30 min before
stimulation with increasing concentrations of CRP-XL or TRAP. The data are presented as MFI  SEM (in arbitrary units) of the results
of two independent experiments with 3 replicates each (n  6) and were analyzed using t tests. ***, P  0.001; *, P  0.05 for NanA
supernatant versus NanA supernatant with apyrase or ticagrelor.
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hyperreactivity. Both oseltamivir acid and 2,3-didehydro-2-deoxy-N-acetylneuraminic
acid (DANA) prevented NanA-induced platelet hyperreactivity in a dose-dependent
manner (Fig. 5).
NanA induces platelet interaction with leukocytes. Sialic acid is negatively
charged, which gives a cell a high electronegative surface charge. Removal of sialic acid
from the platelet surface reduces the overall electronegative charge, and this may
increase intercellular interactions. Analysis of whole blood exposed to NanA showed
increased aggregates of platelets with monocytes, neutrophils, and T cells compared
with the control without NanA (Fig. 6). Addition of oseltamivir showed a reduction in
platelet-leukocyte interaction, although the differences were not statistically signiﬁcant
(see Fig. S4C in the supplemental material).
Variation in the catalytic site of NanA had no effect on platelet hyperreactivity.
Despite the highly conserved activity of NanA, a recent study revealed the evolutionary
diversity of the enzyme (20). Two semiconserved epitopes were identiﬁed in the
catalytic site of NanA, KGI (Lys-Gly-Ile) and RAV (Arg-Ala-Val), which differed in their
Michaelis constants (Kms), the substrate concentration at 1/2 the maximum velocity.
The Km of the RAV variant (NanA-RAV) was found to be signiﬁcantly lower than that of
the KGI variant (NanA-KGI), suggesting that the RAV variant has higher activity. In a
cohort of 281 patients with S. pneumoniae bacteremia, 239 had the KGI variant and 42
had the RAV variant. Platelet counts measured at hospital admission did not differ
FIG 4 Degranulation of dense granules and binding of monoclonal antibodies to surface receptors in
NanA-exposed platelets. (A) CD63 expression and intraplatelet concentrations of mepacrine after treating
PRP with PBS (negative control), puriﬁed neuraminidase (NA), or supernatants with (NanA) and without
(NanA) NanA, followed by stimulation with increasing concentrations of ADP. The data are presented
as MFI  SEM (in arbitrary units) of the results of two independent experiments with 3 replicates each
(n  6). Differences between NanA and –NanA supernatants were analyzed using t tests. (B) Binding
of monoclonal antibodies against P2Y12, GPVI, GPIIIa, and GPIb on platelet surfaces after treating PRP
with increasing concentrations of supernatant containing NanA for 1 h at 37°C. The data are presented
as MFI plus SD (in arbitrary units) of the results of three independent experiments with 3 replicates each.
Increases in expression levels with decreases in dilution of the supernatant were analyzed using 1-way
ANOVA with posttest for the linear trend. ns, not signiﬁcant.
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between the two groups (Fig. 7A). Unfortunately, nadir platelet counts were available
for a few patients in the KGI group only and were therefore not used in the analysis. The
types of disease manifestation and severities of disease were also comparable between
the groups (data not shown). A subset of S. pneumoniae isolates from patients in either
group were cultured, and the supernatants were used to study the effect of NanA-KGI
and NanA-RAV on platelet desialylation. There were no differences in binding of SNA
and MALII lectins to platelet sialic acid between platelets exposed to supernatants of
the KGI or RAV variant (Fig. 7B and C). In addition, there was no difference in
neuraminidase activity between the two NanA variants as measured by a substrate-
FIG 5 Inhibition of NanA by oseltamivir acid and DANA. P-selectin and ﬁbrinogen expression on platelets
was determined after treating PRP with PBS or supernatant containing NanA in the presence of
increasing concentrations of oseltamivir acid or DANA for 1 h at 37°C and then stimulating with 125 M
ADP. The data show MFI  SEM (in arbitrary units) of the results of two independent experiments with
3 replicates each (n  6). Decreases in P-selectin and ﬁbrinogen expression levels with increased
concentrations of oseltamivir acid or DANA in NanA samples were analyzed using 1-way ANOVA with
posttest for the linear trend.
FIG 6 Interaction of NanA-exposed platelets with leukocytes. Levels of platelet interaction with monocytes,
neutrophils, and T cells after treating whole blood with PBS as a negative control, 200 mU puriﬁed
neuraminidase from C. perfrigens (NA), or supernatants with (NanA) and without (NanA) NanA for 1 h
at 37°C. The data are presented as MFI  SEM (in arbitrary units) of the results of two independent
experiments with 3 replicates each (n  6) analyzed using t tests.
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based assay (Fig. 7D). These observations suggest there is no difference in the enzy-
matic activity of NanA variants and no difference in clinical outcomes after infection
with S. pneumoniae isolates producing either variant.
DISCUSSION
In this study, we demonstrate that pneumococcal NanA induces removal of sialic
acid from the platelet surface, resulting in platelet hyperreactivity. These effects were
dependent on ADP signaling and could be prevented by ADP receptor antagonists,
such as ticagrelor, as well as neuraminidase inhibitors, such as oseltamivir acid.
Sialic acid on the platelet surface was determined using the lectins SNA and MALII,
which both bind N-acetylneuraminic acid found on platelet glycoproteins. Pneumo-
cocci also harbor other neuraminidases than NanA, e.g., NanB and NanC, explaining
why supernatant from nanA mutants also induced some sialic acid depletion. While
NanA can cleave -2,3-, -2,6-, and -2,8-linked sialic acids, NanB exhibits a preference
for -2,3-linked sialic acids (17). In our experiments, only the NanA gene was mutated.
Traces of NanB and NanC could still be present in the supernatant, cleaving some of the
-2,3 links that can be detected by MALII, but not SNA. This accounts for the low
binding of MALII, but not SNA lectin, to platelets exposed to the supernatant of the
mutant strain. However, NanA is the strongest neuraminidase and virulence factor for
sialic acid removal. NanB, on the other hand, is involved only in metabolic activities (17,
18). In our experiments, we carefully selected the dilution point of the supernatant
FIG 7 Differential effects of NanA-RAV and NanA-KGI on platelet function. (A) Platelet counts of patients
infected with S. pneumoniae containing the KGI or RAV NanA variant at admission (KGI,
n  239; RAV, n  42). (B and C) Binding of SNA and MALII lectins to surface sialic acid after treating
platelets with supernatants derived from cultures of isolates producing either NanA-RAV or NanA-KGI.
NanA andNanA supernatants were used as positive and negative controls, respectively. The RAV and
KGI groups consisted of four isolates each tested in three platelet donors. (D) Enzymatic activity of the
RAV versus the KGI NanA variants in hydrolyzing sialic acid substrate [2-(4-methylumbelliferyl)-D-N-
acetylneraminic acid]. The data are presented as means with SD and were analyzed using t tests. ns, not
signiﬁcant.
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where the effect of NanB was minimal, diminishing any potential effects of the
contaminant on the observed outcomes of platelet reactivity.
Our ﬁndings show that NanA-induced sialic acid removal does not directly lead to
platelet activation but has an indirect effect, as it leads to increased sensitivity for platelet
activation by other platelet agonists. These ﬁndings are in line with a 1975 report by
Greenberg and colleagues, who found increased agonist-induced platelet aggregation after
removal of sialic acid by neuraminidase (22). However, they conducted a noncontrolled
experiment with the ADP-hydrolyzing agent apyrase, leading to inconclusive results on the
role of ADP. Our study clearly identiﬁed the importance of ADP signaling in NanA-induced
platelet hyperreactivity and showed that both ADP receptor antagonists and neuramini-
dase inhibitors may prevent these effects. Although oseltamivir acid is designed for
inﬂuenza virus neuraminidase, it can effectively inhibit S. pneumoniae neuraminidase due to
close similarities in the active sites of the two proteins (19).
Different mechanisms may explain why NanA-desialylated platelets are hyperreac-
tive, as is also shown in Fig. S5 in the supplemental material. First, the plasma
membrane Orai1 channels contain -2,6-linked sialic acids (23), which can be cleaved
off by NanA. Orai1 mediates calcium inﬂux into the cell, and its desialylation has been
associated with increased calcium uptake (23), a process known to enhance platelet
activation (24). Second, desialylation may lead to a reduction in the negative charge of
the cell membrane, which may enhance transport of positively charged calcium ions
over the cell membrane. Third, binding of desialylated VWF (asialo-VWF) to platelets is
known to induce degranulation of platelet dense granules (25), an effect that can be
blocked by apyrase and ticagrelor (26).
Neuraminidase could act on platelets, as well as on sialylated plasma proteins, such
as ﬁbrinogen, in the PRP. However, several studies have reported that the sialic acid
content of ﬁbrinogen does not affect its interactions with platelets (27, 28). The
observed increase in ﬁbrinogen binding in our assay was therefore unlikely to have
been inﬂuenced by desialylated ﬁbrinogen molecules. Although aggregation of NanA-
exposed platelets was not measured, it is expected, as platelet aggregation correlates
with ﬁbrinogen binding to platelets.
Platelet activation is an important process in inﬂammation and host defense (29–31);
however, hyperreactive platelets may also increase the risk for cardiovascular events. The
importance of cardiovascular complications in pneumococcal infections is increasingly
recognized (9, 32). ADP receptor antagonists are among the most commonly used drugs in
cardiovascular medicine, and neuraminidase inhibitors are frequently prescribed for pa-
tients with pneumonia during the inﬂuenza season; therefore, it is important to better
understand the effects of NanA-mediated desialylation of platelets. From studies in murine
models, it is known that neuraminidase inhibitors may ameliorate sepsis by dampening
inﬂammation (33). Grewal et al. found that clearance of desialylated platelets protects the
host from streptococcus-associated coagulopathy (16). Interestingly, loss of sialic acid is a
well-known platelet clearance mechanism, and in past years, different authors have re-
ported that oseltamivir acid may increase platelet counts under conditions such as immune
thrombocytopenia (15, 34), sepsis (35), and suspected inﬂuenza (36).
Platelet-monocyte clusters, which we observed in vitro, are also observed during S.
pneumoniae infections (4) and are known to mediate the development of cardiovas-
cular events (37). We observed increased platelet-leukocyte aggregates in whole blood
exposed to NanA; however, desialylation of other sialylated blood components (38),
apart from platelets, may have promoted the observed intercellular aggregation.
Platelets engage with leukocytes mainly through the surface P-selectin receptor ex-
pressed on activated platelets. Platelet-leukocyte interactions therefore increase with
increased platelet activation. Removal of sialic acid from cell surfaces reduces the cell
surface electronegative charge, allowing more cell-cell interactions to occur. Our results
show that desialylated platelets are hyperreactive to stimulation. We hypothesize that
under pathological conditions where the vasculature is rich in mediators with the
potential to activate platelets, platelet-leukocyte interactions are also enhanced.
NanA may inﬂuence the binding of agonists to other platelet receptors; however, only
Kullaya et al. Infection and Immunity
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anti-GPIIIa binding increased signiﬁcantly when platelets were exposed to NanA, while no
increased binding of anti-P2Y12, anti-GPIV, or anti-GP1b antibodies was found. Fibrinogen
binding to platelets occurs only after the formation of GPIIb/GPIIIa complexes, which is
driven by activating agents such as ADP (39), which explains the increase in availability of
GPIIIa receptor without ﬁbrinogen binding in unstimulated samples. This observation is
contrary to that of Grewal and colleagues (16), who did not observe a change in binding
of anti-CD61 (GPIIIa) in desialylated platelets. Our results are in line with previous studies
that indicated that glycosylation of P2Y12 receptor (40) or GPVI (41) affects their function
and ligand binding (only GPVI) but not their surface expression. Conversely, ampliﬁcation
of platelet hyperreactivity through ADP signaling may be blunted by neuraminidase, as
Zhong et al. (40) further showed, using CHO cells, that nonglycosylated P2Y12 receptors are
defective in the P2Y12-mediated inhibition of adenylyl cyclase activity.
Xu et al. showed with a molecular simulation model and with puriﬁed NanA variants
containing KGI and RAV motifs in the catalytic domain that NanA-RAV has higher
enzymatic activity than the NanA-KGI variant (20). We could not conﬁrm this result, as
evidence for a difference in neither clinical outcomes nor in vitro platelet activation
assays between the two variants was found. Our ﬁndings suggest, therefore, that
exposure to either variant may have similar clinical consequences. Although we were
not able to demonstrate removal of asialoglycoproteins from the circulation of pneu-
monia patients in our cohort, Grewal et al. have shown, using a mouse model, that
intravenous administration of pneumococcal sialidase leads to platelet desialylation
and subsequent removal from the circulation (16). These observations suggest that a
similar effect could occur in human patients with streptococcus bacteremia.
Siglecs are sialic acid binding receptors on cell surfaces involved in the transduction of
inhibitory signals. Siglec-7 is expressed on platelet surfaces following platelet activation,
where engagement of purinergic receptors, as well as integrin IIb3, is crucial (42).
Siglec-7 binds to -2,3, -2,6, and -2,8 linkages, which can all be cleaved by NanA.
Engagement of Siglec-7 with its ligand leads to platelet apoptosis by the intrinsic pathway
and an extramitochondrial pathway but has no effect on platelet activation, aggregation, or
secretion (42, 43). Although platelet desialylation, particularly of the GP1b receptor, has
been associated with platelet apoptosis, the role of siglec-7 was not discussed (15). Since
siglec-7 induces apoptosis after engagement with its ligand, gangliosides, it would be
expected that removal of platelet sialic acid would affect this apoptotic pathway. Whether
platelet desialylation by NanA interferes with siglec-inhibitory signals requires further
investigation. Given the existing information, it is unlikely that interference of neuramini-
dase with siglec-7 ligands would affect platelet activation.
One limitation of our study is that we did not purify NanA from the culture
supernatants used. However, we controlled for possible effects of other pneumococcus-
derived products in the supernatant by using a control NanA mutant strain with the
same biological properties as the NanA-producing strain except for NanA secretion. We
are therefore conﬁdent that the effects we observed are caused by NanA and not by
other streptococcal exoglycosidases, such as BgaA (a -galactosidase) and StrH (a
-acetylglucosaminidase), which are primarily membrane bound (44).
Collectively, our ﬁndings show that exposure of platelets to soluble NanA induces
removal of sialic acid from the platelet surface, which in turn leads to platelet hyperreac-
tivity and increased interaction with leukocytes. Neuraminidase inhibitors may prevent
these effects on platelets caused by NanA, but the clinical consequences are currently
unknown.
MATERIALS AND METHODS
Ethical statement. Clinical data were obtained from a cohort of adult patients with a ﬁrst episode
of bacteremic pneumococcal pneumonia admitted to two Dutch hospitals, namely, the Canisius-
Wilhelmina Ziekenhuis in Nijmegen and Maasziekenhuis Pantein in Boxmeer, between 2000 and 2011.
This cohort study was approved by the local Medical Ethics Committees of both participating hospitals.
Analyses of the current study were within the goals of the cohort study, and no additional institutional
approval was required. All data and samples used were anonymous.
Construction of a nanA mutant. A directed deletion of nanA was made in the pneumococcal
TIGR4 strain by allelic replacement of the target gene with an antibiotic resistance marker, as described
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previously (45). Brieﬂy, overlap extension PCR was used to insert the spectinomycin resistance cassette
of the pR412 plasmid between the two 500-bp ﬂanking sequences adjacent to the target gene. The
resulting PCR products were introduced by competent stimulating peptide 2 (CSP-2)-induced transfor-
mation into TIGR4. Directed mutants were obtained by selective plating and were checked for correct
integration of the antibiotic resistance cassette into the target gene by PCR using control primers located
inside the gene. Subsequently, the WT TIGR4 strain was transformed with chromosomal DNA isolated
from the mutants to prevent the accumulation of inadvertent mutations elsewhere on the chromosome.
In addition, loss of the target gene was conﬁrmed by quantitative PCR (qPCR). The primers (Biolegio,
Nijmegen, The Netherlands) used in this study are listed in Table S1 in the supplemental material.
Alignment of pneumococcal NanA variants. A total of 281 pneumococcal isolates were obtained
from an unbiased cohort of patients with invasive pneumococcal disease in Nijmegen, The Netherlands,
between 2001 and 2011. All the patients gave written consent to participate. The study was approved
by the Local Medical Ethics Committees of the participating hospitals. Details of clinical data on patient
characteristics, comorbidities, severity of disease, and clinical outcome were described by Cremers et al.
(46). Genomic DNA preparation and whole-genome sequencing were described by Cremers et al. (47).
The NanA sequences were aligned using Multiple-Sequence Comparison by Log Expectation (MUSCLE)
(48) software.
Development of culture supernatants and NanA protein quantiﬁcation. Single bacterial colonies
of WT and nanA TIGR4 were cultured in casein tryptone (CAT) medium supplemented with 0.015 M
K2HPO4, 5 l catalase (Sigma), and 0.02 g N-acetyl-D-mannosamine (ManNAc) and harvested at an optical
density (OD) of 0.2. After removal of remnant bacterial and culture components, the supernatants were
concentrated using Microcon 30-kDa centrifugation ﬁlter devices (Merck Millipore).
The concentrated supernatants were incubated at 100°C for 5 min in sample buffer (60 mM Tris-HCl,
pH 6.8, 2% SDS, 2% -mercaptoethanol, trace bromophenol blue), analyzed on Tris-glycine SDS-PAGE
gels in a Protean II xi cell electrophoresis system (Bio-Rad), and visualized by Coomassie staining.
Densitometry analysis was performed with ImageJ (49). Average spot intensities of NanA (80 kDa) and
bovine serum albumin (BSA) (55 kDa), used as a loading control (marker), were determined. The
absence of the80-kDa band in the NanA mutant conﬁrmed the presence of a protein of this size in the
gel. Average spot intensity of NanA was corrected with the average spot intensity of BSA and depicted
as the relative corrected spot intensity compared to WT TIGR4. Enzymatic activity of NanA in the
supernatant was conﬁrmed by a ﬂuorometric method using 0.45 mM 2-(4-methylumbelliferyl)-D-N-
acetylneuraminic acid as the substrate. Thirty microliters of sample was mixed with equal volumes of
substrate and reaction buffer, pH 7.0, and incubated at 37°C for 2 h, followed by 400 l of stop solution
(containing glycine and Trizol). After centrifugation, the supernatant was transferred onto a clean
reaction plate, and the ﬂuorescence was measured. Total enzymatic activity was calculated in moles of
substrate hydrolyzed per unit per time (hours).
Platelet sialic acid assays. Washed platelets were isolated from 3.2% sodium-citrate-anticoagulated
whole blood (Becton Dickinson), as previously described (50), and resuspended in HEPES Tyrode buffer
at 4 	 108 platelets/ml. The platelets were exposed to serial dilutions of culture supernatant for 1 h at
37°C and washed twice with PBST (PBS plus 0.05% Tween 20) supplemented with 0.01% prostaglandin.
PBS and 200 M puriﬁed NA from Clostridium perfringens (Sigma-Aldrich) were used as negative and
positive controls, respectively. Puriﬁed neuraminidase was used to demonstrate that observed effects
with supernatants containing NanA were similar to those induced by other neuraminidases. Cells were
then stained with the platelet identiﬁcation marker CD61 (Beckman Coulter) and sialic acid binding
lectins SNA and MALII (both from Vector Laboratories) for 30 min at room temperature (RT). The cells
were washed twice, ﬁxed using 0.2% paraformaldehyde, and analyzed using a Cytomics FC500 ﬂow
cytometer and CXP acquisition software (Beckman Coulter).
Platelet function assays and platelet-leukocyte complexes. Platelet function was determined
using a ﬂow cytometry assay, as previously described (51). Whole blood or PRP was incubated with 200
mU puriﬁed neuraminidase and supernatants with and without NanA for 1 h at 37°C, followed by
stimulation with increasing concentrations of ADP, CRP-XL, or TRAP. The cells were labeled with
antibodies directed against CD61, P-selectin (BioLegend) as a marker of platelet degranulation, and
ﬁbrinogen (Dako) as a marker of integrin IIb3 activation. The ADP-stimulatory pathway was blocked by
hydrolyzing ADP using 10 g/ml of apyrase (Sigma-Aldrich) or by blocking the ADP receptor P2Y12 with
50 g/ml ticagrelor (Bio Connect B.V.) for 30 min before addition of stimuli. These concentrations of
apyrase and ticagrelor reduced about 40% of secondary stimulation with 7.8 M ADP for both P-selectin
and ﬁbrinogen binding (see Fig. S4B in the supplemental material). This observation indicates that
apyrase and ticagrelor provide adequate inhibition of the CRP- and TRAP-induced ADP positive-feedback
loop, as activated platelets are expected to release smaller amounts of ADP than the 7.8 M used in our
experiments. Quantiﬁcation of platelet dense granules was performed by incubating NanA-exposed PRP
with 50 M mepacrine for 10 min, followed by ﬂow cytometry analysis to determine the intraplatelet
mepacrine content. Furthermore, dense-granule degranulation was analyzed by measuring the expres-
sion of CD63 (BioLegend) on the platelet membrane. Platelet-leukocyte interactions were determined by
gating CD45-positive cells that were also positive for both platelet (anti-CD42b; BD Biosciences) and
monocyte (CD14), neutrophil (CD56), or T-cell (CD3) markers (Beckman Coulter).
Surface expression of platelet glycoproteins. To study whether desialylation of platelets affects
the surface expression of glycoproteins, PRP was treated with increasing concentrations of WT super-
natant for 1 h at 37°C. Cells were labeled with antibodies against the VWF receptor GPIb (anti-CD42b;
BD Biosciences), the ﬁbrinogen receptor GPIIIa (anti-CD61; Beckman Coulter), the collagen receptor GPVI
(anti-GPVI; BD Biosciences), and the ADP receptor P2Y12 (Fabgennix). The effects of neuraminidase
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inhibitors on platelet function were assessed by treating PRP with supernatant containing NanA in the
presence of increasing concentrations of oseltamivir acid (Bioconnect B.V.) and DANA (Sigma-Aldrich),
followed by stimulation with 125 M ADP.
Statistical analysis. Statistical differences were analyzed using Student’s t test or one-way analysis
of variance (ANOVA), with posttests as indicated. Data are presented as means with standard deviations
(SD) or means with standard errors of the mean (SEM) of independent measurements. Statistical analysis
was done using GraphPad Prism 6 software. Flow cytometry analysis was done using Beckman Coulter
Kaluza software version 1.2.
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